Copyright Reports & Markets. All rights reserved.

Global Myelodysplastic Syndrome (MDS) Treatment Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Myelodysplastic Syndrome (MDS) Treatment Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Myelodysplastic Syndrome (MDS) Treatment Market Size Growth Rate by Product
      • 1.4.2 Azacitidine
      • 1.4.3 Lenalidomide
      • 1.4.4 Decitabine
      • 1.4.5 Deferasirox
    • 1.5 Market by End User
      • 1.5.1 Global Myelodysplastic Syndrome (MDS) Treatment Market Size Growth Rate by End User
      • 1.5.2 Refractory cytopenia with unilineage dysplasia
      • 1.5.3 Refractory anemia with ringed sideroblasts
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Myelodysplastic Syndrome (MDS) Treatment Market Size
      • 2.1.1 Global Myelodysplastic Syndrome (MDS) Treatment Revenue 2014-2025
      • 2.1.2 Global Myelodysplastic Syndrome (MDS) Treatment Sales 2014-2025
    • 2.2 Myelodysplastic Syndrome (MDS) Treatment Growth Rate by Regions
      • 2.2.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales by Regions
      • 2.2.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Myelodysplastic Syndrome (MDS) Treatment Sales by Manufacturers
      • 3.1.1 Myelodysplastic Syndrome (MDS) Treatment Sales by Manufacturers
      • 3.1.2 Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Manufacturers
      • 3.1.3 Global Myelodysplastic Syndrome (MDS) Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.2 Myelodysplastic Syndrome (MDS) Treatment Revenue by Manufacturers
      • 3.2.1 Myelodysplastic Syndrome (MDS) Treatment Revenue by Manufacturers (2014-2019)
      • 3.2.2 Myelodysplastic Syndrome (MDS) Treatment Revenue Share by Manufacturers (2014-2019)
    • 3.3 Myelodysplastic Syndrome (MDS) Treatment Price by Manufacturers
    • 3.4 Myelodysplastic Syndrome (MDS) Treatment Manufacturing Base Distribution, Product Types
      • 3.4.1 Myelodysplastic Syndrome (MDS) Treatment Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Myelodysplastic Syndrome (MDS) Treatment Product Type
      • 3.4.3 Date of International Manufacturers Enter into Myelodysplastic Syndrome (MDS) Treatment Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales by Product
    • 4.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Product
    • 4.3 Myelodysplastic Syndrome (MDS) Treatment Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Myelodysplastic Syndrome (MDS) Treatment Breakdown Data by End User

    6 North America

    • 6.1 North America Myelodysplastic Syndrome (MDS) Treatment by Countries
      • 6.1.1 North America Myelodysplastic Syndrome (MDS) Treatment Sales by Countries
      • 6.1.2 North America Myelodysplastic Syndrome (MDS) Treatment Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Myelodysplastic Syndrome (MDS) Treatment by Product
    • 6.3 North America Myelodysplastic Syndrome (MDS) Treatment by End User

    7 Europe

    • 7.1 Europe Myelodysplastic Syndrome (MDS) Treatment by Countries
      • 7.1.1 Europe Myelodysplastic Syndrome (MDS) Treatment Sales by Countries
      • 7.1.2 Europe Myelodysplastic Syndrome (MDS) Treatment Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Myelodysplastic Syndrome (MDS) Treatment by Product
    • 7.3 Europe Myelodysplastic Syndrome (MDS) Treatment by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Myelodysplastic Syndrome (MDS) Treatment by Countries
      • 8.1.1 Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Sales by Countries
      • 8.1.2 Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Myelodysplastic Syndrome (MDS) Treatment by Product
    • 8.3 Asia Pacific Myelodysplastic Syndrome (MDS) Treatment by End User

    9 Central & South America

    • 9.1 Central & South America Myelodysplastic Syndrome (MDS) Treatment by Countries
      • 9.1.1 Central & South America Myelodysplastic Syndrome (MDS) Treatment Sales by Countries
      • 9.1.2 Central & South America Myelodysplastic Syndrome (MDS) Treatment Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Myelodysplastic Syndrome (MDS) Treatment by Product
    • 9.3 Central & South America Myelodysplastic Syndrome (MDS) Treatment by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment by Countries
      • 10.1.1 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Sales by Countries
      • 10.1.2 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment by Product
    • 10.3 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment by End User

    11 Company Profiles

    • 11.1 Novartis AG
      • 11.1.1 Novartis AG Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Novartis AG Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Novartis AG Myelodysplastic Syndrome (MDS) Treatment Products Offered
      • 11.1.5 Novartis AG Recent Development
    • 11.2 Celgene Corporation
      • 11.2.1 Celgene Corporation Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Celgene Corporation Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Celgene Corporation Myelodysplastic Syndrome (MDS) Treatment Products Offered
      • 11.2.5 Celgene Corporation Recent Development
    • 11.3 Otsuka Pharmaceutical Co., Ltd
      • 11.3.1 Otsuka Pharmaceutical Co., Ltd Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Otsuka Pharmaceutical Co., Ltd Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Otsuka Pharmaceutical Co., Ltd Myelodysplastic Syndrome (MDS) Treatment Products Offered
      • 11.3.5 Otsuka Pharmaceutical Co., Ltd Recent Development
    • 11.4 Sandoz Inc
      • 11.4.1 Sandoz Inc Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Sandoz Inc Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Sandoz Inc Myelodysplastic Syndrome (MDS) Treatment Products Offered
      • 11.4.5 Sandoz Inc Recent Development
    • 11.5 Dr Reddys Laboratories Limited
      • 11.5.1 Dr Reddys Laboratories Limited Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Treatment Products Offered
      • 11.5.5 Dr Reddys Laboratories Limited Recent Development
    • 11.6 Pharmascience Inc
      • 11.6.1 Pharmascience Inc Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Pharmascience Inc Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Pharmascience Inc Myelodysplastic Syndrome (MDS) Treatment Products Offered
      • 11.6.5 Pharmascience Inc Recent Development
    • 11.7 Accord Healthcare Ltd
      • 11.7.1 Accord Healthcare Ltd Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Treatment Products Offered
      • 11.7.5 Accord Healthcare Ltd Recent Development
    • 11.8 Mylan N.V.
      • 11.8.1 Mylan N.V. Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Mylan N.V. Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Mylan N.V. Myelodysplastic Syndrome (MDS) Treatment Products Offered
      • 11.8.5 Mylan N.V. Recent Development

    12 Future Forecast

    • 12.1 Myelodysplastic Syndrome (MDS) Treatment Market Forecast by Regions
      • 12.1.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue Forecast by Regions 2019-2025
    • 12.2 Myelodysplastic Syndrome (MDS) Treatment Market Forecast by Product
      • 12.2.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales Forecast by Product 2019-2025
      • 12.2.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue Forecast by Product 2019-2025
    • 12.3 Myelodysplastic Syndrome (MDS) Treatment Market Forecast by End User
    • 12.4 North America Myelodysplastic Syndrome (MDS) Treatment Forecast
    • 12.5 Europe Myelodysplastic Syndrome (MDS) Treatment Forecast
    • 12.6 Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Forecast
    • 12.7 Central & South America Myelodysplastic Syndrome (MDS) Treatment Forecast
    • 12.8 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Myelodysplastic Syndrome (MDS) Treatment Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      Myelodysplastic (MDS) syndrome is a type of bone marrow disorder, where bone marrow is unable to produce healthy and mature blood cells. The immature blood cells called as blasts, get stored in the bone marrow and blood and obstruct the natural function of the hematological system which results in depletion of healthy red blood cells, platelets, and white blood cells. Myelodysplastic syndrome is usually seen in geriatric population and more often in older men than women. This syndrome is characterized by certain chromosomal mutations in Janus Kinase gene which include deletion of q arm in one or more chromosomes and complete deletion of chromosome 5 or 7 and an extra copy of chromosome 8.
      According to the American Cancer Society, the incidence rate for myelodysplastic syndrome is 13,000 new cases each year which happens at a rate of 4.8 cases per 100,000 people. This trend is heavily affected or rather influenced by the average age of the population which, according to the World Health Organization (WHO), is increasing and is expected to double from 12% to 22% between 2015 and 2050.
      The global Myelodysplastic Syndrome (MDS) Treatment market is valued at 2210 million US$ in 2018 and will reach 5760 million US$ by the end of 2025, growing at a CAGR of 12.7% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Myelodysplastic Syndrome (MDS) Treatment market based on company, product type, end user and key regions.

      This report studies the global market size of Myelodysplastic Syndrome (MDS) Treatment in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Myelodysplastic Syndrome (MDS) Treatment in these regions.
      This research report categorizes the global Myelodysplastic Syndrome (MDS) Treatment market by top players/brands, region, type and end user. This report also studies the global Myelodysplastic Syndrome (MDS) Treatment market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Novartis AG
      Celgene Corporation
      Otsuka Pharmaceutical Co., Ltd
      Sandoz Inc
      Dr Reddys Laboratories Limited
      Pharmascience Inc
      Accord Healthcare Ltd
      Mylan N.V.

      Market size by Product
      Azacitidine
      Lenalidomide
      Decitabine
      Deferasirox
      Market size by End User
      Refractory cytopenia with unilineage dysplasia
      Refractory anemia with ringed sideroblasts
      Others

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Myelodysplastic Syndrome (MDS) Treatment market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Myelodysplastic Syndrome (MDS) Treatment market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Myelodysplastic Syndrome (MDS) Treatment companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Myelodysplastic Syndrome (MDS) Treatment submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Myelodysplastic Syndrome (MDS) Treatment are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Myelodysplastic Syndrome (MDS) Treatment market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now